Spark Therapeutics, Inc. (ONCE) Stock Price Down 0.6% Following Insider Selling

Shares of Spark Therapeutics, Inc. (NASDAQ:ONCE) traded down 0.6% on Tuesday after an insider sold shares in the company. The company traded as low as $66.13 and last traded at $72.65. 551,300 shares were traded during trading, an increase of 39% from the average session volume of 395,797 shares. The stock had previously closed at $72.25.

Specifically, CEO Jeffrey D. Marrazzo sold 20,000 shares of the firm’s stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.54, for a total value of $1,430,800.00. Following the sale, the chief executive officer now owns 250,000 shares of the company’s stock, valued at approximately $17,885,000. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Barge Joseph La sold 5,500 shares of the firm’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $81.00, for a total transaction of $445,500.00. Following the completion of the sale, the insider now directly owns 10,825 shares in the company, valued at approximately $876,825. The disclosure for this sale can be found here. In the last three months, insiders sold 1,099,659 shares of company stock worth $92,457,658. Insiders own 7.30% of the company’s stock.

ONCE has been the subject of several research analyst reports. Jefferies Group LLC reaffirmed a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a research report on Tuesday, October 10th. SunTrust Banks, Inc. set a $101.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a research report on Monday, October 16th. Cowen and Company reaffirmed a “buy” rating and issued a $95.00 target price on shares of Spark Therapeutics in a research report on Tuesday, October 10th. Royal Bank Of Canada dropped their target price on shares of Spark Therapeutics from $100.00 to $98.00 and set an “outperform” rating for the company in a research report on Wednesday, November 8th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $111.00 target price on shares of Spark Therapeutics in a research report on Friday, October 6th. Three research analysts have rated the stock with a sell rating, one has issued a hold rating and eighteen have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $90.36.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) EPS for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The company had revenue of $1.90 million during the quarter, compared to the consensus estimate of $1.40 million. During the same quarter in the prior year, the firm earned ($1.07) earnings per share. The business’s revenue was up 45.8% compared to the same quarter last year. equities research analysts expect that Spark Therapeutics, Inc. will post -7.62 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in ONCE. BlackRock Inc. grew its position in Spark Therapeutics by 11,332.0% during the first quarter. BlackRock Inc. now owns 1,840,214 shares of the biotechnology company’s stock valued at $98,158,000 after buying an additional 1,824,117 shares during the period. Janus Henderson Group PLC bought a new stake in Spark Therapeutics during the second quarter valued at approximately $30,848,000. Orbimed Advisors LLC bought a new stake in Spark Therapeutics during the third quarter valued at approximately $38,340,000. Jennison Associates LLC bought a new stake in Spark Therapeutics during the third quarter valued at approximately $27,239,000. Finally, JPMorgan Chase & Co. grew its position in Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after buying an additional 241,016 shares during the period. Institutional investors own 77.94% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://www.themarketsdaily.com/2017/11/16/spark-therapeutics-inc-once-stock-price-down-0-6-following-insider-selling.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply